Tanvex Business Summary

Tanvex BioPharma, Inc. (6541.TW) is a vertically integrated biopharmaceutical company specializing in the development, manufacturing, and commercialization of high-complexity biosimilars and biologics. Following its landmark January 2025 acquisition of Bora Biologics, the company has transitioned to a dual-engine revenue model: commercializing its proprietary biosimilar pipeline—including the FDA-approved Nypozi (TX01) and trastuzumab biosimilar (TX05)—while operating a global Contract Development and Manufacturing Organization (CDMO) platform. Its primary business segments are Biosimilar Product Development and Biologics CDMO Services, leveraging cGMP-certified facilities in San Diego, California, and Zhubei, Taiwan, to provide end-to-end solutions from cell-line development to commercial-scale production. In the competitive landscape, Tanvex contends with global giants such as Sandoz, Amgen, and Celltrion, positioning itself as a high-agility partner that bridges Asian cost-efficiencies with rigorous U.S. regulatory expertise and commercial infrastructure. The company was founded by Dr. Allen Chao, the visionary founder of Watson Pharmaceuticals, who continues to serve as Honorary Chairman. As of March 2026, the leadership is spearheaded by Chairman Bobby Sheng—also Chairman of Bora Pharmaceuticals—who orchestrated the strategic integration to scale Tanvex’s global footprint. The executive team is led by CEO Stephen Lam, a 35-year industry veteran formerly of Thermo Fisher and Amgen, supported by Chief Commercial Officer Marc Goemans and COO John Mosack. Tanvex is backed by a powerful institutional investor base, with Bora Pharmaceuticals serving as the largest shareholder (holding approximately 30.5%), alongside significant positions held by the Chao family and Delos Capital. This leadership structure combines deep generic-pharmaceutical pedigree with modern biologics manufacturing scale, aiming to establish the firm as a top-tier global CDMO player.